STOCK TITAN

Cooper Stock Price, News & Analysis

COO NASDAQ

Company Description

Overview of CooperCompanies

CooperCompanies (NYSE: COO) is a globally recognized medical device company dedicated to enhancing quality of life through innovative healthcare solutions. Headquartered in San Ramon, California, the company operates through two primary business units: CooperVision and CooperSurgical. With a presence in over 130 countries and a workforce exceeding 15,000 employees, CooperCompanies combines cutting-edge technology with a mission-driven approach to address critical healthcare needs.

CooperVision: Transforming Vision Care

CooperVision is a leader in the contact lens industry, offering a comprehensive portfolio of products designed to improve vision for millions of people worldwide. Its product range includes spherical, multifocal, and toric lenses, as well as specialty lenses crafted from advanced materials like silicone hydrogel. These lenses cater to diverse vision correction needs, such as astigmatism and presbyopia, and are available under well-known brands like Biofinity, MyDay, and Clariti.

What sets CooperVision apart is its commitment to innovation and practitioner support. The company collaborates closely with eye care professionals to deliver tailored solutions that enhance patient outcomes. Its specialty lens portfolio, one of the most extensive globally, underscores its dedication to addressing complex vision challenges. As a key player in the vision care market, CooperVision competes with industry giants like Johnson & Johnson and Alcon, leveraging its expertise and product diversity to maintain a strong market share.

CooperSurgical: Advancing Women’s Health

CooperSurgical focuses on improving healthcare delivery for women by providing a wide array of medical devices and treatment options. Its offerings span fertility treatments, reproductive care, and general women’s health solutions. The company is particularly notable for its comprehensive coverage of the in vitro fertilization (IVF) cycle, making it a trusted partner for fertility clinics worldwide.

Key products include the Paragard hormone-free intrauterine device (IUD), which holds a significant share of the U.S. IUD market, and innovative surgical technologies like the ONETRAC™ portfolio of retractors. CooperSurgical’s dedication to addressing critical healthcare moments for women, babies, and families positions it as a leader in its field.

Global Reach and Market Presence

CooperCompanies has established a robust global footprint, with products sold in over 130 countries. Its dual focus on vision care and women’s health not only diversifies its revenue streams but also mitigates risks associated with market-specific challenges. The company’s strategic acquisitions, such as the integration of obp Surgical, further strengthen its product portfolio and market presence.

Commitment to Innovation and Quality

Innovation is at the core of Cooper’s operations. The company invests heavily in research and development to stay ahead in the competitive medical device landscape. Its focus on high-quality, clinically relevant products ensures that it meets the evolving needs of healthcare providers and patients alike. Additionally, Cooper’s adherence to stringent regulatory standards, including the EU Medical Devices Regulation (MDR), underscores its commitment to safety and compliance.

Challenges and Opportunities

While CooperCompanies enjoys a strong market position, it faces challenges such as regulatory complexities, supply chain disruptions, and intense competition. However, its diversified portfolio and strategic focus on high-growth areas like specialty contact lenses and fertility solutions provide significant opportunities for sustained growth. The company’s ability to integrate acquisitions effectively and innovate continuously will be crucial to its long-term success.

Conclusion

CooperCompanies exemplifies a balanced approach to healthcare innovation, combining a strong product portfolio with a commitment to improving lives. Its leadership in vision care and women’s health, coupled with a global reach and focus on quality, positions it as a key player in the medical device industry. Investors and stakeholders can view Cooper as a company that not only addresses current healthcare needs but is also well-equipped to adapt to future challenges and opportunities.

Stock Performance

$81.09
+0.25%
+0.20
Last updated: April 27, 2025 at 16:00
-10.05 %
Performance 1 year
$16.4B
Market Cap
200.0M
Shares outstanding

SEC Filings

No SEC filings available for Cooper.

Financial Highlights

$964,700,000
Revenue (TTM)
$104,300,000
Net Income (TTM)
$0.52
Diluted EPS (TTM)
$190,600,000
Operating Cash Flow
10.81%
Net Profit Margin
18.87%
Oper. Profit Margin

Upcoming Events

Frequently Asked Questions

What is the current stock price of Cooper (COO)?

The current stock price of Cooper (COO) is $80.89 as of April 25, 2025.

What is the market cap of Cooper (COO)?

The market cap of Cooper (COO) is approximately 16.4B.

What is the revenue (TTM) of Cooper (COO) stock?

The trailing twelve months (TTM) revenue of Cooper (COO) is $964,700,000.

What is the net income of Cooper (COO)?

The trailing twelve months (TTM) net income of Cooper (COO) is $104,300,000.

What is the earnings per share (EPS) of Cooper (COO)?

The diluted earnings per share (EPS) of Cooper (COO) is $0.52 on a trailing twelve months (TTM) basis.

What is the operating cash flow of Cooper (COO)?

The operating cash flow of Cooper (COO) is $190,600,000.

What is the profit margin of Cooper (COO)?

The net profit margin of Cooper (COO) is 10.81%.

What is the operating margin of Cooper (COO)?

The operating profit margin of Cooper (COO) is 18.87%.

What is the gross margin of Cooper (COO)?

The gross profit margin of Cooper (COO) is 68.44%.

What is the current ratio of Cooper (COO)?

The current ratio of Cooper (COO) is 1.99, indicating the company's ability to pay short-term obligations.

What is the gross profit of Cooper (COO)?

The gross profit of Cooper (COO) is $660,200,000 on a trailing twelve months (TTM) basis.

What is the operating income of Cooper (COO)?

The operating income of Cooper (COO) is $182,000,000.

What are the main business segments of CooperCompanies?

CooperCompanies operates through two primary segments: CooperVision, focusing on vision care, and CooperSurgical, specializing in women's health and fertility solutions.

How does CooperVision differentiate itself in the contact lens market?

CooperVision offers a diverse range of high-quality lenses, including specialty lenses for complex vision needs, and collaborates closely with eye care professionals.

What products does CooperSurgical offer?

CooperSurgical provides medical devices for fertility treatments, reproductive care, and general women’s health, including hormone-free IUDs and IVF-related technologies.

What challenges does CooperCompanies face?

Cooper faces challenges such as regulatory compliance, market competition, and supply chain disruptions but mitigates risks through diversification and innovation.

In which countries does CooperCompanies operate?

CooperCompanies has a global presence, with products sold in over 130 countries.

What is CooperCompanies’ approach to innovation?

The company invests heavily in R&D to develop high-quality, clinically relevant products and maintains compliance with stringent regulatory standards.

How does CooperCompanies generate revenue?

Revenue is primarily generated through the sale of medical devices in vision care and women’s health, targeting both healthcare providers and end consumers.

What makes CooperSurgical a leader in fertility solutions?

CooperSurgical offers comprehensive IVF cycle coverage and innovative products like the hormone-free Paragard IUD, making it a trusted partner for fertility clinics.